Newborn Screening Result Analyte Additions for Iowa and North Dakota
The State Hygienic Laboratory at the University of Iowa (SHL), in cooperation with the Iowa Department of Health and Human Services and the North Dakota Department of Health and Human Services, is adding the following result analytes to each state’s newborn screening panel beginning with specimens received on Tuesday, February 3, 2026. Please read your state’s client memo and ask your IT staff to build the new result analytes into your EMR. There are no changes in the collection and transportation of specimens or in the ordering process of the newborn screening panel.
Iowa
New analytes:
- Krabbe disease interpretation
- Krabbe Disease 2nd Tier NBS interpretation (for specimens that are presumptive positive for the Krabbe disease interpretation)
Newborn Screening Results Specifications Iowa 2026-02-03
North Dakota
New analytes:
- Mucopolysaccharidosis Type II (MPSII) disease interpretation
- Mucopolysaccharidosis (MPS) 2nd Tier NBS interpretation (for specimens that are presumptive positive for the Mucopolysaccharidosis Type II (MPSII) disease interpretation)
- Krabbe disease interpretation
- Krabbe Disease 2nd Tier NBS interpretation (for specimens that are presumptive positive for the Krabbe disease interpretation)
- X-linked Adrenoleukodystrophy disease interpretation
Newborn Screening Results Specifications North Dakota 2026-02-03